4D MOLECULAR THERAPEUTICS IN
FDMTNASDAQTrading Snapshot
- Day Range
- $14.11 – $14.53
- 52-Week Range
- $6.96 – $16.93
- Volume
- $2.35B
- Avg Volume
- $2.53B
- Shares Outstanding
- 52.3M
- Next Earnings
- Nov 16, 2026
Fundamentals Snapshot
- Annual Revenue
- $85M
- Last Q Revenue
- $4M
- P/E Ratio
- -5.3
- P/S Ratio
- 8.1x
- EPS (TTM)
- $-2.55
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +7.4%
Why Investors Own FDMT
- ✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 72% gross margin and 12% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
4D MOLECULAR THERAPEUTICS IN
FDMT
StockOtter · stockotter.spaceAbout 4D MOLECULAR THERAPEUTICS IN
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
4D Molecular Therapeutics remains a 'Buy' as its gene therapy 4D-150 advances in phase 3 trials for wet AMD and diabetic macular edema [DME]. Topline data from the pivotal 4FRONT-1 and 4FRONT-2 wet AMD studies are expect
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
EMERYVILLE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT; 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with po
Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $13.65,
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $28.56 Average PT from Brokerages
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One an
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript